In this video, health-care analyst David Williamson walks investors through today's Aveo Pharmaceuticals (NASDAQ:AVEO) bloodbath. Shares are down 50% as an FDA advisory committee voted overwhelmingly against its drug candidate tivozanib. Find out why the decision shook out like it did, and if Aveo is a bad news buy after today's extreme plunge.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Will This iPhone Supplier’s Terrific Run Continue in 2018?
Lumentum's growing momentum in 3D sensing could help it overcome the weakness in the telecom segment.
3 Companies Best Positioned to Compete Against Amazon
There's more than one way to beat Amazon at its own game.
Time to Get Greedy With Home Depot Stock
2018 is shaping up to be another big year for the home-improvement specialist.